Medtech Rises To Challenge Of Meeting Infinite Heath Care Demand With Finite Resources

Dec 14 2018

Listen to this article

The relative absence of blockbuster M&A within medtech in 2018, compared with recent years, does not mean that consolidation of the industry – and of providers and payers – will not continue apace in 2019 and beyond. In fact, it is written – if not in the stars then possibly in digital coding – that there will be fewer and bigger entities at the top end of the ecosystem of medtech stakeholders. And rising demand will be met more and more by digital tools and functionalities.

Health care is on a journey to a fully-digitized and personalized diagnostic environment, where health systems can host genomics data and individual family history data, rendering far more precise diagnoses for patients. That is the goal. But health-care systems are under pressure because "we have finite resources but almost infinite demand." So says Neil Mesher, of Royal Philips UK and Ireland.

Mesher was a speaker at the UK ABHI's 30th anniversary event in November 2018, where the consensus was around the...

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

Dec 13 2022

• By Ashley Yeo

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Infographic: Top 100 Pharma Companies

Dec 13 2022

• By Lucie Ellis-Taitt

The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.

Pfizer Leads An Unusual Year For The Scrip 100

Dec 13 2022

• By Jessica Merrill

Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.

Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

Dec 12 2022

• By Jo Shorthouse

What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

Scrip 100: By The Numbers

Dec 06 2023

• By Lucie Ellis-Taitt and Kosh Naran

Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.